On December 8, 2022 Fresenius Kabi reported that it has introduced Pralatrexate Injection, a drug for the treatment of relapsed or refractory peripheral T-cell lymphoma in the U.S. Fresenius Kabi Pralatrexate Injection that is a generic of Folotyn and is available to customers immediately (Press release, Fresenius, DEC 8, 2022, View Source [SID1234624949]). It is the newest addition to the company’s injectable oncology medicine portfolio, the largest in U.S. health care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!